# | ||||
---|---|---|---|---|
1 | TRIC-TB Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments. | 2019 | 8˙373˙250.00 | 6˙926˙375.00 |
The Institution BIOVERSYS AG has been involved also in the following Horizon 2020 projects.